Fresenius Medical Care - Renal Therapies Group & Fresenius Kidney Care, a Division of FMCNA

920 Winter Street
Waltham, MA 02451
800-662-1237 or 781-699-9000
Renal Therapies Group –
Fresenius Kidney Care –

Renal Therapies Group
The Renal Therapies Group (RTG), a division of Fresenius Medical Care North America (FMCNA), is passionately committed to helping people with chronic kidney disease (CKD) and end-stage renal disease (ESRD) lead more active and fulfilling lives. RTG is pivotal part of a group of collaborating companies across FMCNA dedicated to one mission: Providing superior care that improves the quality of life of every patient, every day. Through its two divisions — Renal Technologies and Renal Pharmaceuticals — RTG delivers hemodialysis and peritoneal dialysis equipment and ancillary products, as well as renal pharmaceuticals, to the CKD community, in both the clinical and home environments.

  • Fresenius Renal Technologies provides in-center (clinical) and home dialysis products in support of nearly 200,000 patients battling CKD and ERSD.
    • Key offerings include Optiflux® dialyzers (the most prescribed brand in the market), Crit-Line® (revolutionary fluid management technology), 2008T Hemodialysis Machines (in-center hemodialysis), 2008K@home™ Hemodialysis Machines (home hemodialysis) and Liberty® Cyclers (home peritoneal dialysis), as well as ancillary products, including bloodlines and concentrates.
  • Fresenius Renal Pharmaceuticals is the partner of choice for biotech and pharmaceutical companies seeking to provide pharmaceutical treatment to CKD patients. The pharmaceuticals team collaborates closely with the CKD community to market, educate, and distribute vital pharmaceutical therapies through a model focused on serving the CKD community with innovative products and services.
    • Key offerings include: Velphoro® (the first non-calcium, iron-based chewable phosphate binder for the control of serum phosphorus levels in patients with CKD on dialysis), Venofer® (an iron sucrose injection providing first-line IV therapy for the treatment of iron deficiency anemia in patients with CKD), and Phoslyra® (a calcium acetate oral solution indicated for the reduction of serum phosphorus in patients with ESRD).

For more information, visit


Fresenius Kidney Care, A Division of Fresenius Medical Care NA
Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and services to nearly 200,000 people with kidney disease at more than 2,200 facilities nationwide. Fresenius Kidney Care supports people by helping to address both the physical and emotional aspects of kidney disease through personalized care, education and lifestyle support services so they can lead meaningful and fulfilling lives.

Fresenius Kidney Care patients have access to FMCNA’s integrated network of kidney care services ranging from cardiology and vascular care to pharmacy and lab services as well as urgent care centers and the country’s largest practice of hospitalist and post-acute providers.

As a leader in renal care technology, innovation and clinical research, FMCNA’s more than 67,000 employees are dedicated to the mission of delivering superior care that improves the quality of life for people with kidney disease.

For more information about Fresenius Kidney Care, visit, like us on Facebook at and follow us on Twitter at